EGRF conjugated PEGylated nanographene oxide for targeted chemotherapy and photothermal therapy

Biomaterials

Volumn 34, Issue 29, 2013, Pages 7204-7214

  Yang, Hung Wei ^a,b   Lu, Yu Jen ^b   Lin, Kun Ju ^b   Hsu, Sheng Chieh ^c   Huang, Chiung Yin ^b   She, Shu Han ^a   Liu, Hao Li ^d   Lin, Chih Wen ^a   Xiao, Min Cong ^d   Wey, Shiaw Pyng ^d   Chen, Pin Yuan ^b   Yen, Tzu Chen ^b   Wei, Kuo Chen ^b   Ma, Chen Chi M ^a  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^d CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Chemotherapy; EGFR; Growth signal blocking; Nanographene oxide; Photothermal therapy; Tumor targeting

Indexed keywords

CHEMOTHERAPEUTIC AGENTS; EGFR; EPIDERMAL GROWTH FACTOR RECEPTORS; MULTIDRUG RESISTANCE; PHOTOTHERMAL THERAPY; SIGNAL BLOCKING; TARGETED CHEMOTHERAPY; TUMOR TARGETING;

CHEMOTHERAPY;

TUMORS;

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIRUBICIN; GRAPHENE OXIDE; NANOCONJUGATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG DISTRIBUTION; DRUG RELEASE; DRUG TARGETING; DRUG TUMOR LEVEL; GLIOMA; GLIOMA CELL; MOUSE; NONHUMAN; PHOTOTHERAPY; PRIORITY JOURNAL; SURVIVAL TIME;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, IMMOBILIZED; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; EPIRUBICIN; GLIOMA; GRAPHITE; HUMANS; MICE; NANOSTRUCTURES; OXIDES; PHOTOTHERAPY; POLYETHYLENE GLYCOLS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

MUS;

EID: 84879605060     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.06.007     Document Type: Article

References (31)

1. Halatsch M.E., Schmidt U., Behnke-Mursch J., Unterberg A., Wirtz C.R. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer Treat Rev 2006, 32:74-89.
2. Argyriou A.A., Antonacopoulou A., Iconomou G., Kalofonos H.P. Treatment options for malignant gliomas, emphasizing towards new molecularly targeted therapies. Crit Rev Oncol Hematol 2009, 69:199-210.
3. Baselga J. The EGFR as a target for anticancer therapy-focus on cetuximab. Eur J Cancer 2001, 37:16-22.
4. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. NEngl J Med 2004, 350:2129-2139.
5. Vermeer P.D., Einwalter L.A., Moninger T.O., Rokhlina T., Kern J.A., Zabner J., et al. Segregation of receptor and ligand regulates activation of epithelial growth factor receptor. Nature 2003, 422:322-326.
6. Sorkin A. Internalization of the epidermal growth factor receptor: role in signaling. Biochem Soc Trans 2001, 29:480-484.
7. Zhou Y., Drummond D.C., Zou H., Hayes M.E., Adams G.P., Kirpotin D.B., et al. Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. JMol Biol 2007, 371:934-947.
8. Van Cutsem E., Peeters M., Siena S., Humblet Y., Hendlisz A., Neyns B., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. JClin Oncol 2007, 25:1658-1664.
9. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Shin D.M., Cohen R.B., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. NEngl J Med 2006, 354:567-578.
10. Atkinson R.L., Zhang M., Diagaradjane P., Peddibhotla S., Contreras A., Hilsenbeck S.G., et al. Thermal enhancement with optically activated gold nanoshells sensitizes breast cancer stem cells to radiation therapy. Sci Transl Med 2010, 2:55. ra79.
11. Chandna P., Khandare J.J., Ber E., Rodriguez-Rodriguez L., Minko T. Multifunctional tumor-targeted polymer-peptide-drug delivery system for treatment of primary and metastatic cancers. Pharm Res 2010, 27:2296-2306.
12. Yuan F., Dellian M., Fukumura D., Leunig M., Berk D.A., Torchilin V.P., et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995, 55:3752-3756.
13. Allen T.M., Cullis P.R. Drug delivery systems: entering the mainstream. Science 2004, 303:1818-1822.
14. Stayton P.S., Hoffman A.S., Murthy N., Lackey C., Cheung C., Tan P., et al. Molecular engineering of proteins and polymers for targeting and intracellular delivery of therapeutics. JControl Release 2000, 65:203-220.
15. Novoselov K.S., Geim A.K., Morozov S.V., Jiang D., Zhang Y., Dubonos S.V., et al. Electric field effect in atomically thin carbon films. Science 2004, 306:666-669.
16. Compton O.C., Nguyen S.T. Graphene oxide, highly reduced graphene oxide, and graphene: versatile building blocks for carbon-based materials. Small 2010, 6:711-723.
17. Liu Z., Robinson J.T., Sun X., Dai H. PEGylated nanographene oxide for delivery of water-insoluble cancer drugs. JAm Chem Soc 2008, 130:10876-10877.
18. Lu C.H., Yang H.H., Zhu C.L., Chen X., Chen G.N. Agraphene platform for sensing biomolecules. Angew Chem Int Ed 2009, 48:4785-4787.
19. Yang K., Zhang S., Zhang G., Sun X., Lee S.T., Liu Z. Graphene in mice: ultrahigh invivo tumor uptake and efficient photothermal therapy. Nano Lett 2010, 10:3318-3323.
20. Sun X., Liu Z., Welsher K., Robinson J.T., Goodwin A., Zaric S., et al. Nano-graphene oxide for cellular imaging and drug delivery. Nano Res 2008, 1:203-212.
21. Karmali P.P., Kotamraju V.R., Kastantin M., Black M., Missirlis D., Tirrell M., et al. Targeting of albumin-embedded paclitaxel nanoparticles to tumors. Nanomedicine 2009, 5:73-82.
22. Dyke C.A., James M. Unbundled and highly functionalized carbon nanotubes from aqueous reactions. Nano Lett 2003, 3:1215-1218.
23. Wang J.Y., Yang S.Y., Huang Y.L., Tien H.W., Chin W.K., Ma C.C.M. Preparation and properties of graphene oxide/polyimide composite films with low dielectric constant and ultrahigh strength via in situ polymerization. JMater Chem 2011, 21:13569-13575.
24. Hamm B., Staks T., Taupitz M., Maibauer R., Speidel A., Huppertz A., et al. Contrast-enhanced MR imaging of liver and spleen: first experience in humans with a new superparamagnetic iron oxide. JMagn Reson Imaging 1994, 4:659-668.
25. Yang X., Zhang X., Liu Z., Ma Y., Huang Y., Chen Y. High-efficiency loading and controlled release of doxorubicin hydrochloride on graphene oxide. JPhys Chem C 2008, 112:17554-17558.
26. Kataoka K., Matsumoto T., Yokoyama M., Okano T., Sakurai Y., Fukushima S., et al. Doxorubicin-loaded poly(ethylene glycol)-poly(β-benzyl-l-aspartate) copolymer micelles: their pharmaceutical characteristics and biological significance. JControl Release 2000, 64:143-153.
27. Depan D., Shah J., Misra R.D.K. Controlled release of drug from folate-decorated and graphene mediated drug delivery system: synthesis, loading efficiency, and drug release response. Mat Sci Eng C-mater 2011, 31:1305-1312.
28. Gillies E.R., Frechet J.M. pH-responsive copolymer assemblies for controlled release of doxorubicin. Bioconjug Chem 2005, 16:361-368.
29. Hua M.Y., Yang H.W., Liu H.L., Tsai R.Y., Pang S.P., Chuang K.L., et al. Superhigh-magnetization nanocarrier as a doxorubicin delivery platform for magnetic targetingtTherapy. Biomaterials 2011, 32:8999-9010.
30. Tian B., Wang C., Zhang S., Feng L., Liu Z. Photothermally enhanced photodynamic therapy delivered by nano-graphene oxide. ACS Nano 2011, 5:7000-7009.
31. Zhang W., Guo Z., Huang D., Liu Z., Guo X., Zhong H. Synergistic effect of chemo-photothermal therapy using PEGylated graphene oxide. Biomaterials 2011, 32:8555-8561.